替格瑞洛联合尿激酶溶栓治疗ST段抬高型心肌梗死的临床效果分析

Clinical effects of ticagrelor combined with urokinase thrombolytic therapy in treatment of ST-segment elevation myocardial infarction

目的:探讨替格瑞洛联合尿激酶溶栓治疗ST段抬高型心肌梗死(STEMI)的临床效果。方法:选取某院收治的98例STEMI患者,利用随机数字表法分为2组,每组各49例。2组均使用尿激酶溶栓治疗,在此基础上对照组加用氯吡格雷,观察组加用替格瑞洛。对比2组患者的临床治疗效果、冠脉造影结果、心肌损伤标志物水平、炎性因子水平以及不良事件发生率。结果:对照组治疗总有效率低于观察组,差异具有统计学意义(P<0.05);观察组ST回落>50%比例优于对照组,差异有统计学意义(P<0.05);治疗后2组患者LVEF,LVEDd指标观察组高于对照组,差异具有统计学意义(P<0.05);2组患者治疗后血清TNF-α,IL-6,cTnI,CK-MB水平比较,观察组低于对照组,差异具有统计学意义(P<0.05);2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:STEMI患者采取替格瑞洛与尿激酶联合溶栓治疗可有效提升临床疗效,减轻患者心肌损伤,且临床不良反应较轻,具有较好的安全性。

Objective: To analyze the clinical effects of ticagrelor combined with urokinase thrombolytic therapy in treatment of ST-segment elevation myocardial infarction (STEMI). Methods :98 STEMI patients treated in a hospital were randomly divided into a control group and an observation group,49 cases in each group.The two groups were given urokinase thrombolytic therapy,and on this basis,the control group was given clopidogrel while the observation group was given ticagrelor. The curative effects, coronary angiography results, levels of myocardial damage marker, levels of inflammatory factor,and incidence of adverse events were compared between the two groups. Results :Compared with the observation group, the total effective rate of the control group was lower (P<0.05).ST decreased>50% in the observation group,which was significantly superior to that in the control group (P<0.05).After the treatment,LVEF, LVEDd in the two groups significantly increased, and the observation group was higher than the control group (P<0.05).After the treatment, the levels of serum TNF-α, IL-6, cTnI,and CK-MB in the two groups significantly decreased,with the observation group's being lower than those of the control group (P<0.05).The incidence of adverse reactions between the two groups had no statistical difference (P>0.05). Conclusion :Ticagrelor combined with urokinase thrombolytic therapy in treatment of STEMI is effective.It can reduce myocardial damage and achieve slighter adverse reactions, which has better safety.